Editorial

One-month DAPT after acute coronary syndrome: too short or not too short?

EuroIntervention 2022;18:443-445. DOI: 10.4244/EIJ-E-22-00022

Piera Capranzano
Piera Capranzano1, MD, PhD
1. Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
A mandatory period of dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y12 inhibitor is recommended after percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). However, the optimal DAPT duration, minimising bleeding risk while preserving efficacy, is still debated. Shortening DAPT by dropping the aspirin or the P2Y12 inhibitor and continuing with an indefinite maintenance of antiplatelet monotherapy is among the main strategies to reduce bleeding. Indeed, the introduction of newer drug-eluting stents (DES) with improved safety has allowed for the testing of increasingly abbreviated periods of DAPT. One month is the shortest DAPT duration ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Defer-based non-stenting: a promising approach for STEMI

Latest news